Navigation Links
NIH scientists find mechanism that helps HIV evade antibodies, stabilize key proteins
Date:2/3/2014

WHAT:

NIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HIV neutralizing antibodies bind, findings with potential implications for HIV vaccine research. Numerous spikes jut out of the surface of HIV, each containing a set of three identical, bulb-shaped proteins called gp120 that can be closed together or spread apart like the petals of a flower. Some of the most important sites targeted by HIV neutralizing antibodies are hidden when the three gp120s, or the trimer, are closed, and the gp120 trimer remains closed until the virus binds to a cell.

The researchers discovered that certain amino acids located on the gp120 protein undergo a process that stabilizes the trimer in its closed position. In this process, called sulfation, the amino acids acquire a sulfur atom surrounded by four oxygen atoms. By either blocking or increasing sulfation of these amino acids, the researchers changed the sensitivity of the virus to different neutralizing antibodies, indicating that the trimer was being either opened or closed.

The scientists suggest that if the synthesized gp120 widely used in HIV research were fully sulfated during manufacture, the resulting product would adopt a more true-to-life structure and more closely mirror the way the immune system sees unbound HIV. This might help generate a more effective HIV vaccine. The researchers add that full sulfation of gp120 may enable scientists to crystallize the molecule more readily, which also could advance HIV vaccine design.

ARTICLE:

R Cimbro et al. Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.1314718111 (2014).

WHO:

Paolo Lusso, M.D., Ph.D., chief of the Viral Pathogenesis Section in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases, is available for comment.


'/>"/>

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Scientists develop powerful new animal model for metastatic prostate cancer
2. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
3. Scripps Florida scientists find regulator of amyloid plaque buildup in Alzheimers disease
4. NCCS scientists discover gene regulation is dependent on protein ANP32E
5. Scientists make your stomach turn bright green if you have an ulcer
6. Scientists reduce protein crystal damage, improve pharmaceutical development
7. It's All In The Climate: New Study from Research Scientists at Florida International University Predict
8. Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
9. Scientists discover that short-term energy deficits increase factors related to muscle degradation
10. CNIO scientists create the first large catalog of interactions between drugs and proteins
11. Over 70 new centers to train tomorrows engineers and scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... Massachusetts (PRWEB) , ... April 24, 2017 , ... ... will help busy nursing professionals advance their careers. Beginning in the fall of 2017, ... Nursing (BSN) degree in as few as 16 months and for as little as ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology: